Your browser doesn't support javascript.
loading
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.
Moinzadeh, Pia; Bonella, Francesco; Oberste, Max; Weliwitage, Jithmi; Blank, Nobert; Riemekasten, Gabriela; Müller-Ladner, Ulf; Henes, Jörg; Siegert, Elise; Günther, Claudia; Kötter, Ina; Pfeiffer, Christiane; Schmalzing, Marc; Zeidler, Gabriele; Korsten, Peter; Susok, Laura; Juche, Aaron; Worm, Margitta; Jandova, Ilona; Ehrchen, Jan; Sunderkötter, Cord; Keyßer, Gernot; Ramming, Andreas; Schmeiser, Tim; Kreuter, Alexander; Lorenz, Hanns-Martin; Hunzelmann, Nicolas; Kreuter, Michael.
Afiliação
  • Moinzadeh P; Department of Dermatology and Venereology, University Hospital Cologne, Cologne, Germany. Electronic address: pia.moinzadeh@uk-koeln.de.
  • Bonella F; Center for Interstitial and Rare Lung Diseases, Ruhrlandklinik, Pneumonology Department, University of Duisburg-Essen, Essen, Germany.
  • Oberste M; Institute of Medical Statistics and Computational Biology, Faculty of Medicine, University Hospital Cologne, Cologne, Germany.
  • Weliwitage J; Institute of Medical Statistics and Computational Biology, Faculty of Medicine, University Hospital Cologne, Cologne, Germany.
  • Blank N; Division of Rheumatology, Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Riemekasten G; Clinic for Rheumatology and Clinical Immunology, University Hospital Schleswig-Holstein, University of Lübeck, Lübeck, Germany.
  • Müller-Ladner U; Department of Rheumatology, Kerckhoff Clinic, Bad Nauheim, Germany.
  • Henes J; Centre for Interdisciplinary Rheumatology, Auto-inflammatory Diseases and Internal Medicine 2, University Hospital Tübingen, Tübingen, Germany.
  • Siegert E; Department of Rheumatology and Clinical Immunology, Charité - Universitaetsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany.
  • Günther C; Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
  • Kötter I; Division of Rheumatology and Systemic Inflammatory Diseases, University Hospital Hamburg, Rheumatology Clinic, Bad Bramstedt, Germany.
  • Pfeiffer C; Department of Dermatology and Allergology, University Medical Center Ulm, Ulm, Germany.
  • Schmalzing M; Rheumatology/Clinical Immunology, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
  • Zeidler G; Department of Rheumatology, Osteology and Pain Therapy, Center for Rheumatology Brandenburg, Johanniter-Hospital Treuenbrietzen, Treuenbrietzen, Germany.
  • Korsten P; Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany.
  • Susok L; Department of Dermatology, Venereology and Allergology, St. Josef Hospital Bochum, Bochum, Germany.
  • Juche A; Department of Rheumatology, Immanuel Hospital Berlin-Buch, Berlin, Germany.
  • Worm M; Department of Dermatology, Venereology and Allergology, Charité - Universitaetsmedizin Berlin, Berlin, Germany.
  • Jandova I; Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, Germany.
  • Ehrchen J; Department of Dermatology, University Hospital Münster, Münster, Germany.
  • Sunderkötter C; Departments of Dermatology, University Hospital Halle (Saale), Halle, Germany.
  • Keyßer G; Internal Medicine, Division of Rheumatology, University Hospital Halle (Saale), Halle, Germany.
  • Ramming A; Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.
  • Schmeiser T; Internal Medicine - Rhematology and Osteology, Hospital St. Josef, Wuppertal, Germany.
  • Kreuter A; Department of Dermatology, Venereology and Allergology, Helios St Elisabeth Hospital Oberhausen, University Witten/Herdecke, Oberhausen, Germany.
  • Lorenz HM; Division of Rheumatology, Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Hunzelmann N; Department of Dermatology and Venereology, University Hospital Cologne, Cologne, Germany.
  • Kreuter M; Mainz Center for Pulmonary Medicine, Departments of Pneumology, Mainz University Medical Center and of Pulmonary, Critical Care & Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany.
Chest ; 165(1): 132-145, 2024 01.
Article em En | MEDLINE | ID: mdl-37582424
ABSTRACT

BACKGROUND:

Pulmonary involvement is the leading cause of death in systemic sclerosis (SSc) and may manifest as interstitial lung disease (ILD), pulmonary arterial hypertension (PAH), or in combination of both (ILD with pulmonary hypertension [ILD-PH]). The aim of this analysis was to determine prevalence, clinical characteristics, and survival of these different forms within the registry of the German Network for Systemic Sclerosis. RESEARCH QUESTION Does SSc-associated ILD-PH or ILD without PH affect survival differently, and are there any risk factors that have an additional impact? STUDY DESIGN AND

METHODS:

Clinical data of 5,831 patients with SSc were collected in the German Network for Systemic Sclerosis registry. Kaplan-Meier estimates were used to compare overall survival in patients with SSc-associated ILD-PH and ILD without PH with patients without pulmonary involvement and those with PAH. The Cox proportional hazard model was used to analyze the influence of pulmonary involvement and other potential predictors on patient survival.

RESULTS:

Clinical data of 3,257 patients with a mean follow-up time of 3.45 ± 1.63 years have been included in our analysis. At baseline, ILD was present in 34.5%, whereas PH without ILD had a lower prevalence with 4.5%. At the end of follow-up, 47.6% of patients with SSc had ILD, 15.2% had ILD-PH, and 6.5% had PAH. ILD was more frequent in the diffuse cutaneous form (57.3%), whereas PAH did not differ significantly between SSc subtypes. Significant differences in baseline characteristics between PAH vs ILD-PH vs ILD without PH were found for age at diagnosis, sex, SSc subsets, antibody status, FVC, diffusing capacity of the lung for carbon monoxide, and therapy. Overall survival at 5 years was 96.4% for patients without pulmonary involvement and differed significantly between patients with ILD without PH, PAH, and being worst in patients with ILD-PH. Female sex (hazard ratio [HR], 0.3), higher BMI (HR, 0.9), and higher diffusing capacity of the lung for carbon monoxide values (HR, 0.98) were associated with a lower mortality risk.

INTERPRETATION:

ILD is the most prevalent pulmonary involvement in SSc, whereas the combination of ILD and PH is associated with the most detrimental survival.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Escleroderma Sistêmico / Doenças Pulmonares Intersticiais / Hipertensão Arterial Pulmonar / Hipertensão Pulmonar Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Escleroderma Sistêmico / Doenças Pulmonares Intersticiais / Hipertensão Arterial Pulmonar / Hipertensão Pulmonar Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article